Vuoristo Mikko, Vihinen Pia, Vlaykova Tatyana, Nylund Camilla, Heino Jyrki, Pyrhönen Seppo
Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
Melanoma Res. 2007 Aug;17(4):215-23. doi: 10.1097/CMR.0b013e328270b935.
Expression of collagen receptor integrins alpha1beta1 and alpha2beta1 has been associated with progression and metastatic potential of malignant melanoma. Integrin alpha2beta1 was originally characterized as a melanoma progression antigen. We have used real-time quantitative PCR to study the mRNA expression levels of three collagen receptor integrin chains, that is alpha1, alpha2 and alpha11 in metastases from 26 patients with melanoma. Interestingly, we find that survival after initiation of chemoimmunotherapy was significantly decreased in all patients whose tumours expressed high mRNA levels of alpha1 integrin, alpha2 integrin or alpha11 integrin when compared with lower tumour expression levels (P<0.05, log rank test). Moreover, those patients with high mRNA levels of all studied integrins had a significantly shorter survival from the appearance of the first metastasis than the patients with low levels of integrins (P<0.05). Furthermore, a high mRNA expression level of integrin alpha2 was found to be associated with poorer overall survival. High alpha2 mRNA levels (n=6) were associated with median survival of 35 months and low alpha2 mRNA levels (n=20), with median survival of 53 months (P=0.033). We conclude that collagen receptor integrins are important in the progression and prognosis of metastatic melanoma, and their measurements might be used as predictive markers when assessing disease progression.
胶原蛋白受体整合素α1β1和α2β1的表达与恶性黑色素瘤的进展及转移潜能相关。整合素α2β1最初被鉴定为黑色素瘤进展抗原。我们运用实时定量PCR研究了26例黑色素瘤患者转移灶中三种胶原蛋白受体整合素链,即α1、α2和α11的mRNA表达水平。有趣的是,我们发现与肿瘤表达水平较低的患者相比,所有肿瘤中α1整合素、α2整合素或α11整合素mRNA表达水平高的患者在开始化学免疫治疗后的生存率显著降低(P<0.05,对数秩检验)。此外,所有研究整合素mRNA水平高的患者从首次转移出现起的生存期明显短于整合素水平低的患者(P<0.05)。此外,发现整合素α2的高mRNA表达水平与总体生存率较差相关。α2 mRNA高水平(n = 6)与中位生存期35个月相关,α2 mRNA低水平(n = 20)与中位生存期53个月相关(P = 0.033)。我们得出结论,胶原蛋白受体整合素在转移性黑色素瘤的进展和预后中起重要作用,在评估疾病进展时,其检测结果可用作预测标志物。